Skip to content
etf.net

Launched · SEC filings

Virtus Biotech Clinical Trials ETF

BBCNYSE ArcaD

$40.64−2.42 (−5.61%)

As of Oct 13, 2026, 3:59 PM

D34/ 100

Rank 15 of 17 in Biotech & Genomics

D34/100Rank 15 of 17inBiotech & Genomics
Intraday session: down, 41 prints from 43.06 to 40.64. Range 40.64 to 43.06. Use the arrow keys to read each point.41.0041.5042.0042.5010 AM12 PM2 PM4 PM
Expense ratio
0.65%
Fund size
$42M
1Y total return
+51.2%
Yield · Last 12 months
1.52%
Holdings
130
Avg volume · 30D
0M sh
NAV per share
$44.12
52W range
low $28.73high $56.18
Launched
Filings
SEC EDGAR

The ETF.net BBC Grade

D

Score 34 out of 100

Category
Biotech & Genomics⁠
Rank
15 of 17
Six-pillar profile for BBC. Scores out of 100: Cost 13, Risk 26, Mission 47, Tradability 21, Holdings 93, Durability 50. Strongest: Holdings (93). Weakest: Cost (13). Leans toward Holdings.

Score 34 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F13 out of 100
    Rank 15 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    C47 out of 100
    Rank 8 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D26 out of 100
    Rank 16 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F21 out of 100
    Rank 15 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A93 out of 100
    Rank 1 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C50 out of 100
    Rank 11 of 17

Our read on BBC

ETF.net Research

DMost biotech funds blend approved-drug cash machines with science projects. BBC keeps only the science projects: US-listed biotechs whose lead drug is still in clinical trials, spread across roughly 200 names.

Stated mandate

The Fund seeks to track, before fees and expenses, the investment results of the LifeSci Biotechnology Clinical Trials Index. The Index comprises U.S.-listed biotechnology stocks with a lead drug in clinical-stage development.

Why people hold it

  1. 01A genuinely narrow mandate: the index takes U.S.-listed biotechs with a lead drug in clinical-stage development, so commercial-stage giants stay out.
  2. 02Roughly 200 holdings, so one failed readout is a dent, not the whole fund.
  3. 03The basket lines up tightly with what the prospectus says it owns, one of the cleaner mandate-to-portfolio matches in biotech.
  4. 04Running since 2014, which makes it one of the longer-lived pure clinical-stage plays rather than a recent theme launch.

Worth knowing

  1. 01At 0.65% a year it costs more than the typical biotech fund, and more than broad peers like XBI (0.35%) and IBB (0.44%).
  2. 02Small asset base and thin trading, so spreads can widen and large orders move the price.
  3. 03Pre-approval biotech is binary by nature, and on our review the fund sits in the lower tier of its biotech peer group overall.

BBC Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
130
Top-10 weight
14%
Largest holding
KOD2.2%

Sectors

  • Health Care100.0%

Geography

  • United States89.83%
  • Canada2.43%
  • Netherlands2.01%
  • Ireland1.56%
  • United Kingdom1.46%
  • China1.05%
  • Switzerland1.04%
  • Germany0.61%
The fund’s holdings, weight-ordered — page 1 of 9.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001KODKodiak Sciences Inc2.22%9,317$930K64
002ABCLAbCellera Biologics Inc1.81%60,560$760K11
003XNCRXencor Inc1.51%25,737$634K93
004AMLXAmylyx Pharmaceuticals Inc1.46%21,750$612K71
005TRAXFirst Tracks Biotherapeutics Inc1.37%17,989$573K63
006ANLAdlai Nortye Group Ltd1.15%30,749$480K5
007REPLReplimune Group Inc1.14%35,736$480K55
008FDMT4D Molecular Therapeutics Inc1.14%35,938$479K63
009PCVXVaxcyte Inc1.14%6,686$477K109
010MBXMBX Biosciences Inc1.14%8,936$476K77
011DFTXDefinium Therapeutics Inc1.13%12,822$473K68
012SLSSELLAS Life Sciences Group Inc1.13%40,528$472K59
013ORICORIC Pharmaceuticals Inc1.10%38,372$460K69
014PRMEPrime Medicine Inc1.09%114,355$456K57
015VORVor BioPharma Inc1.05%22,098$440K55

Showing 1–15 of 130 holdings

BBC Performance

Launched Dec 16, 2014

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BBC$15,115
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. BBC $15,115. SPY $12,044. Use the arrow keys to read each point.$8,976$14,701$20,425Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBC. Periods over one year show the average yearly return.
PeriodBBC
Year to date+11.9%
1 month−12.7%
3 months−18.9%
1 year+51.2%
3 yearsper year+34.3%
5 yearsper year−0.3%
10 yearsper year+8.0%

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BBC
YearReturn barBBC
2026 YTD+11.9%
2025+63.7%
2024−1.1%
2023−1.8%
2022−35.1%
2021−22.3%
2020+30.3%

BBC in the news

Filtered to BBC · Biotech & Genomics

BBC Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
1.52%Last 12 months
Payout per share
$0.66Last 12 months
Last payment
$0.66 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2017–2026

One bar per payment. 4 payments from 2017 to 2026 YTD. Dec 20, 2017 $0.30; Dec 20, 2023 $0.08; Dec 20, 2024 $0.24; Dec 22, 2025 $0.66. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 22, 2025Dec 29, 2025$0.66
Dec 20, 2024Dec 27, 2024$0.24
Dec 20, 2023Dec 29, 2023$0.08
Dec 20, 2017Dec 27, 2017$0.30
Dec 21, 2015Dec 29, 2015$0.15

BBC Risk

How much the fund’s monthly returns vary, scaled to a year.
35.9%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.88
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−70.1%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.26
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BBC Cost

Expense ratio0.65%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

14 of the 17 Biotech & Genomics funds charge less.

BBC costs $65.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others